A Phase III randomised, double-blind, multicentre study to evaluate the safety and efficacy of 1592U89 (abacavir) in human immunodeficiency virus 1-infected patients with aquired immune deficiency syndrome dementia complex

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2006
This article has no abstract
Epistemonikos ID: bdd14987061ddb64d8f0f0f9d240fe742ba55ddf
First added on: Oct 16, 2021